Cancer is physical. How aggressive it is, how fast it spreads, and how it resists treatment depend on biomechanical forces that you cannot see in genomics, radiology, or pathology. You need an additional way to analyze the cell. That is what Artidis delivers.
For cancer to metastasize, cells must physically squeeze through tissue barriers and slip into blood vessels. Artidis identifies the most aggressive cells by measuring mechanical properties within the tumor microenvironment: cancer cells, surrounding matrix, immune landscape, and physical barriers that block treatment penetration.
These are actionable insights. In the coming years, clinicians could base therapeutic decisions on these quantifiable mechanical properties. From taxanes that target cell structure to checkpoint inhibitors that must physically navigate tissue barriers. Artidis provides the predictive biomarkers to guide these choices, offering faster, actionable answers across the care journey.
Add a biomechanical layer to your research. Identify novel biomarkers, understand treatment resistance, and improve model predictivity by measuring tumors in their complete microenvironment.
.svg)
Artidisnet integrates nanomechanical measurements with molecular, clinical, and imaging data—giving clinicians a fast, secure path from measurement to treatment decision.
Our platform brings AFM to routine point-of-care use, profiling cells in its native microenvironment quickly and reproducibly. Our assays preserve tissue integrity during the measurement while unlocking predictive biomarkers.
Measure cancer mechanics within hours at the bedside for earlier diagnosis, better risk assessment, and improved treatment matching. Our predictive biomarker can help guide therapy sequencing (e.g. platinum vs. taxanes), checkpoint inhibitor optimization, and radiation dosing.
Whether you are advancing cancer care, researching new therapeutic pathways, or building novel diagnostics, Artidis provides the tools and insights you need.
